Should we consider calcimimetics as a therapeutic option for nephrotic syndrome? - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Kidney International Année : 2022

Should we consider calcimimetics as a therapeutic option for nephrotic syndrome?

Résumé

Calcimimetics allosterically increase the calcium ion sensitivity of the calcium-sensing receptor (CaSR). Using a CaSR knockdown in podocytes and a podocyte-specific CaSR knockout in mice, Mühlig et al. uncovered a stabilizing role for actin cytoskeleton and cell adhesion. Short-term alleviation of albuminuria and proteinuria was observed in 4 children treated with cinacalcet. Here we discuss the potential mechanisms whereby CaSR displays a favorable effect in podocytes and the context in which calcimimetics may alleviate nephrotic syndrome.
Fichier non déposé

Dates et versions

inserm-03788305 , version 1 (26-09-2022)

Identifiants

Citer

Olivia Lenoir, Pierre-Louis Tharaux. Should we consider calcimimetics as a therapeutic option for nephrotic syndrome?. Kidney International, 2022, 101 (6), pp.1110-1112. ⟨10.1016/j.kint.2022.04.008⟩. ⟨inserm-03788305⟩

Collections

INSERM UP-SANTE
6 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More